In clinical trials, patients using GLP-1s experienced an average body weight reduction of 15% of their body weight
If you are navigating Medicaid coverage delays or denials, combining genetic insights with clinical documentation may strengthen your provider's case during prior authorization or appeal
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) begin affecting appetite and blood sugar within days to weeks, but clinically meaningful outcomes develop more gradually
They emphasize the importance of personalized treatment plans and having regular conversations with patients
[16] [17] Common examples include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)